MVASI™ IS APPROVED FOR THE TREATMENT OF 5 DIFFERENT CANCER TYPES1
For information about your specific diagnosis, please make a selection below:
YOUR DOCTOR HAS SAID THAT YOU HAVE A TYPE OF CANCER CALLED mRCC
Renal cell carcinoma is the most common type of kidney cancer. It occurs when cancer cells form in the tubules of the kidney. Tubules are tiny tubes in your kidney that help filter waste products from your blood and make urine.2,3
It is called mRCC, or metastatic renal cell carcinoma, if cancer cells spread to other parts of the body.4
mRCC OCCURS IN ONE OF THREE WAYS:4
Cancer cells in your kidney spread into the tissue around the tumor.
The cancer moves from your kidney into your lymphatic system, which has vessels throughout the body.
Kidney cancer cells enter the bloodstream and are carried and deposited to another organ or area in your body.
YOUR TREATMENT TEAM IS THERE TO HELP
Because mRCC can impact you and your loved ones' lives, it is important to work closely with your treatment team. If you have questions, reach out to your doctor’s office directly for more information.
Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.
VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT RENAL CELL CARCINOMA
Important Safety Information
Possible serious side effects
Everyone reacts differently to MVASI™ therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
Most serious side effects (not common, but sometimes fatal):
Other possible serious side effects
Side effects seen most often
In clinical studies across different types of cancer, some patients experienced the following side effects:
MVASI™ is not for everyone
Talk to your doctor if you are:
If you have any questions about your condition or treatment, talk to your doctor.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Product Information for additional Important Safety Information.
Metastatic Colorectal Cancer (mCRC)
MVASI™ is approved to treat metastatic colorectal cancer (mCRC) for:
MVASI™ is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MVASI™, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Recurrent Glioblastoma (rGBM)
MVASI™ is approved to treat recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC)
MVASI™, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Advanced Cervical Cancer (CC)
MVASI™, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Avastin® (bevacizumab) is a registered trademark of Genentech USA, Inc.
References: 1. MVASI™ (bevacizumab-awwb) Prescribing Information, Amgen. 2. American Cancer Society. What is kidney cancer?Accessed March 2, 2020. 3. National Cancer Institute. Renal cell cancer treatment - patient version. General information about renal cell cancer. Accessed March 2, 2020. 4. National Cancer Institute. Renal cell cancer treatment - patient version. Stages of renal cell cancer. Accessed March 2, 2020.